Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): AA-Telmisartan-Amlodipine (02473496), AA-Telmisartan-Amlodipine (02473488). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

TELMISARTAN & AMLODIPINE BESYLATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C09D) — coverage varies; not interchangeable

  • Candesartan cilexetil + hydrochlorothiazide (Atacand Plus): general benefit
  • Hydrochlorothiazide + irbesartan (Avalide): general benefit, Not a benefit
  • Hydrochlorothiazide + losartan (Hyzaar): general benefit
  • Hydrochlorothiazide + olmesartan medoxomil (Olmetec Plus): general benefit
  • Hydrochlorothiazide + telmisartan (Micardis Plus): general benefit
  • Hydrochlorothiazide + valsartan (Diovan-HCT): general benefit

1 more in the class list below

Riva-Telmisartan / Amlodipine · DIN 02559854 · 40mg & 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Riva-Telmisartan / Amlodipine · DIN 02559854 Manufacturer: Laboratoire Riva Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-11-13 · brand RIVA-TELMISARTAN/AMLODIPINE · ATC C09DB04 TELMISARTAN AND AMLODIPINE, C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients TELMISARTAN 40 MG, AMLODIPINE (AMLODIPINE BESYLATE) 5 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Telmisartan / Amlodipine: Formulary list price $0.4470/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4470 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106296 · Verify on the e-Formulary ↗ (DIN 02559854)

Source record
DIN 02559854: Riva-Telmisartan / Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800296; group id 353; item number 0815; lccId None; manufacturer id RIA Source form: Tab; strength: 40mg & 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4470; ministry $0.4470 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559854 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106296
Interchangeable products
Twynsta · DIN 02371022 · $0.4470
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559854
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Telmisartan / Amlodipine · DIN 02559862 · 40mg & 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Riva-Telmisartan / Amlodipine · DIN 02559862 Manufacturer: Laboratoire Riva Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-10-21 · brand RIVA-TELMISARTAN/AMLODIPINE · ATC C09DB04 TELMISARTAN AND AMLODIPINE, C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 10 MG, TELMISARTAN 40 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Telmisartan / Amlodipine: Formulary list price $0.4470/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4470 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106297 · Verify on the e-Formulary ↗ (DIN 02559862)

Source record
DIN 02559862: Riva-Telmisartan / Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800298; group id 353; item number 0814; lccId None; manufacturer id RIA Source form: Tab; strength: 40mg & 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4470; ministry $0.4470 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559862 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106297
Interchangeable products
Twynsta · DIN 02371030 · $0.4470
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559862
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Twynsta · DIN 02371022 · 40mg & 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Twynsta · DIN 02371022 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-02-29 Health Canada: Marketed since 2011-08-11 · brand TWYNSTA · ATC C09DB04 TELMISARTAN AND AMLODIPINE, C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG, TELMISARTAN 40 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4470 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85622 · Verify on the e-Formulary ↗ (DIN 02371022)

Source record
DIN 02371022: Twynsta Raw flags: chronicUseMed=Y, sec3=Y Item: 240800296; group id 353; item number 0815; lccId None; manufacturer id BOE Source form: Tab; strength: 40mg & 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.8481; ministry $0.4470 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371022 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85622
Interchangeable products
Riva-Telmisartan / Amlodipine · DIN 02559854 · $0.4470
Shortage status: resolved shortage (ended 2026-02-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371022
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Twynsta · DIN 02371030 · 40mg & 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Twynsta · DIN 02371030 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-02-29 Health Canada: Marketed since 2011-08-11 · brand TWYNSTA · ATC C09DB04 TELMISARTAN AND AMLODIPINE, C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 10 MG, TELMISARTAN 40 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4470 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85623 · Verify on the e-Formulary ↗ (DIN 02371030)

Source record
DIN 02371030: Twynsta Raw flags: chronicUseMed=Y, sec3=Y Item: 240800298; group id 353; item number 0814; lccId None; manufacturer id BOE Source form: Tab; strength: 40mg & 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.8481; ministry $0.4470 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371030 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85623
Interchangeable products
Riva-Telmisartan / Amlodipine · DIN 02559862 · $0.4470
Shortage status: resolved shortage (ended 2020-11-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371030
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Telmisartan / Amlodipine · DIN 02559870 · 80mg & 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Riva-Telmisartan / Amlodipine · DIN 02559870 Manufacturer: Laboratoire Riva Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-10-21 · brand RIVA-TELMISARTAN/AMLODIPINE · ATC C09DB04 TELMISARTAN AND AMLODIPINE, C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG, TELMISARTAN 80 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Telmisartan / Amlodipine: Formulary list price $0.3648/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3648 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106298 · Verify on the e-Formulary ↗ (DIN 02559870)

Source record
DIN 02559870: Riva-Telmisartan / Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800297; group id 353; item number 0817; lccId None; manufacturer id RIA Source form: Tab; strength: 80mg & 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3648; ministry $0.3648 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559870 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106298
Interchangeable products
Twynsta · DIN 02371049 · $0.3648
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559870
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Telmisartan / Amlodipine · DIN 02559889 · 80mg & 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Riva-Telmisartan / Amlodipine · DIN 02559889 Manufacturer: Laboratoire Riva Inc.; listing date 2025-12-30 Health Canada: Marketed since 2025-10-21 · brand RIVA-TELMISARTAN/AMLODIPINE · ATC C09DB04 TELMISARTAN AND AMLODIPINE, C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 10 MG, TELMISARTAN 80 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Telmisartan / Amlodipine: Formulary list price $0.3648/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3648 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106299 · Verify on the e-Formulary ↗ (DIN 02559889)

Source record
DIN 02559889: Riva-Telmisartan / Amlodipine Raw flags: chronicUseMed=Y, sec3=Y Item: 240800299; group id 353; item number 0816; lccId None; manufacturer id RIA Source form: Tab; strength: 80mg & 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3648; ministry $0.3648 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02559889 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106299
Interchangeable products
Twynsta · DIN 02371057 · $0.3648
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02559889
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Twynsta · DIN 02371049 · 80mg & 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Twynsta · DIN 02371049 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-02-29 Health Canada: Marketed since 2011-08-11 · brand TWYNSTA · ATC C09DB04 TELMISARTAN AND AMLODIPINE, C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 5 MG, TELMISARTAN 80 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3648 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85624 · Verify on the e-Formulary ↗ (DIN 02371049)

Source record
DIN 02371049: Twynsta Raw flags: chronicUseMed=Y, sec3=Y Item: 240800297; group id 353; item number 0817; lccId None; manufacturer id BOE Source form: Tab; strength: 80mg & 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.8481; ministry $0.3648 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371049 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85624
Interchangeable products
Riva-Telmisartan / Amlodipine · DIN 02559870 · $0.3648
Shortage status: resolved shortage (ended 2023-02-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371049
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Twynsta · DIN 02371057 · 80mg & 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Twynsta · DIN 02371057 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2012-02-29 Health Canada: Marketed since 2011-08-11 · brand TWYNSTA · ATC C09DB04 TELMISARTAN AND AMLODIPINE, C09DB04 TELMISARTAN AND AMLODIPINE · form Tablet · route Oral · ingredients AMLODIPINE (AMLODIPINE BESYLATE) 10 MG, TELMISARTAN 80 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3648 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85625 · Verify on the e-Formulary ↗ (DIN 02371057)

Source record
DIN 02371057: Twynsta Raw flags: chronicUseMed=Y, sec3=Y Item: 240800299; group id 353; item number 0816; lccId None; manufacturer id BOE Source form: Tab; strength: 80mg & 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.8481; ministry $0.3648 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371057 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85625
Interchangeable products
Riva-Telmisartan / Amlodipine · DIN 02559889 · $0.3648
Shortage status: resolved shortage (ended 2026-02-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371057
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

IRBESARTAN & HYDROCHLOROTHIAZIDE

· 36 products · General benefit (35), Listed, not a benefit (1) · strengths: 150mg & 12.5mg, 300mg & 12.5mg, 300mg & 25mg · Tab

LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE

· 34 products · General benefit · strengths: 100mg & 12.5mg, 50mg & 12.5mg, 100mg & 25mg · Tab

OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE

· 27 products · General benefit · strengths: 20mg & 12.5mg, 40mg & 12.5mg, 40mg & 25mg · Tab

TELMISARTAN & HYDROCHLOROTHIAZIDE

· 22 products · General benefit · strengths: 80mg & 12.5mg, 80mg & 25mg · Tab

VALSARTAN & HYDROCHLOROTHIAZIDE

· 34 products · General benefit · strengths: 80mg & 12.5mg, 160mg & 12.5mg, 160mg & 25mg, 320mg & 12.5mg, 320mg & 25mg · Tab

EPROSARTAN MESYLATE & HYDROCHLOROTHIAZIDE

· 1 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 600mg & 12.5mg · Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TWYNSTA (telmisartan/amlodipine besylate) is indicated for: • treatment of mild to moderate essential hypertension for whom combination therapy with telmisartan and amlodipine is appropriate. TWYNSTA is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of TWYNSTA in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics • Geriatrics (> 65 years of age): No dose adjustment is necessary for geriatric patients. It should be recognized, however, that greater sensitivity in some older individuals cannot be ruled out. https://pdf.hres.ca/dpd_pm/00077924.PDF PM date: AUG 11, 2011 Source product: TWYNSTA; DIN 02371022; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.